$33.29 Billion Forecast for Non-Small Cell Lung Cancer (NSCLC) Market by 2029, Backed by Demand and Innovation
Discover trends, market shifts, and competitive outlooks for the non-small cell lung cancer (nsclc) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Non-Small Cell Lung Cancer (NSCLC) Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market scale for non-small cell lung cancer (NSCLC) has seen a swift upturn in the past few years. It is projected to escalate from $20.1 billion in 2024 to about $22.35 billion by 2025, boasting a compound annual growth rate (CAGR) of 11.1%. The enlargement of this market in the historic period is a result of the progress in immunotherapy, genomics profiling, precision medicine, the broadening of clinical trials, along with initiatives aim at stopping smoking.
Anticipated to experience swift expansion in the coming years, the non-small cell lung cancer (NSCLC) market has a projected worth of $33.29 billion in 2029, with a compound annual growth rate (CAGR) of 10.5%. Factors contributing to the growth during the forecast period include the adoption of combination therapies, the incorporation of artificial intelligence (AI), development of personalized vaccines, worldwide collaborative research efforts, and a focus on patient-centric care. Noteworthy trends projected for the forecast period incorporate the application of telemedicine in oncology, the introduction of liquid biopsy technologies, advancements in diagnostic techniques, the use of minimally invasive surgery methods, and the employment of immune checkpoint inhibitors.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
What Are the Core Growth Drivers Propelling the Non-Small Cell Lung Cancer (NSCLC) Market Forward?
The surge in tobacco usage is projected to drive the expansion of the non-small cell lung cancer (NSCLC) market. The reference to tobacco consumption pertains to the utilization of tobacco goods by individuals, largely through smoking, chewing, or snuffing, introducing nicotine and other chemicals into their system. A number of carcinogens present in tobacco smoke have the potential to harm the DNA in lung cells, which can result in mutations and unchecked growth of malignant cells, including non-small cell lung cancer (NSCLC). As an illustration, the US Food and Drug Administration (USFDA) in October 2024, reported in the 2024 National Youth Tobacco Survey that 1.1% of all students (roughly 2.25 million) were currently using tobacco products. This includes 10.1% of high school students (about 1.58 million) and 5.4% of middle school children (around 640,000); moreover, 2.8% of the students (about 760,000) confessed to current use of any combustible tobacco product, and 3.0% (approximately 840,000) admitted to using multiple tobacco products. Hence, the surging rate of tobacco usage is anticipated to drive the non-small cell lung cancer (NSCLC) market’s growth. Non-Small Cell Lung Cancer (NSCLC) Market Driver: Increased Instances of Non-Small Cell Lung Cancer (NSCLC) Linked to Growing Air Pollution Levels
What Segment Types Define the Non-Small Cell Lung Cancer (NSCLC) Market Structure?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented –
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Emerging Trends that Are Influencing theNon-Small Cell Lung Cancer (NSCLC) Industry Evolution?
Major corporations involved in the non-small cell lung cancer (NSCLC) marketplace are concentrating their efforts on generating various treatment methods, including monotherapy treatments, in the quest to establish a competitive advantage. A therapy like monotherapy heavily involves using only one treatment type or procedure for a medical condition, as opposed to an integration of various strategies. For example, Novartis AG, a pharmaceutical corporation located in Switzerland, was granted authorization by the European Commission (EC), a regulatory authority in Belgium, to use Tabrecta (capmatinib) for adult patients suffering from advanced non-small cell lung cancer with METex14 skipping in June 2022. This presents a fresh targeted therapy option for European patients previously treated for advanced non-small cell lung cancer (NSCLC) containing mutations triggering MET exon 14 (METex14) skipping. It is currently the foremost targeted therapy for advanced NSCLC with variations that lead to METex14 skipping.
View the full report here:
What Is the Definition of the Non-Small Cell Lung Cancer (NSCLC) Market?
Non-small cell lung cancer (NSCLC) is a type of epithelial lung cancer that develops in the tissues of the lungs and is characterized by the abnormal growth of cells. It is primarily caused by long-term smoking, genetic mutations, air pollution, and secondhand smoke.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
